ACLX
Price
$66.00
Change
-$0.57 (-0.86%)
Updated
Jan 22, 03:52 PM (EDT)
Capitalization
3.6B
57 days until earnings call
BEAM
Price
$24.53
Change
+$1.09 (+4.65%)
Updated
Jan 21 closing price
Capitalization
2.03B
41 days until earnings call
Ad is loading...

ACLX vs BEAM

Header iconACLX vs BEAM Comparison
Open Charts ACLX vs BEAMBanner chart's image
Arcellx
Price$66.00
Change-$0.57 (-0.86%)
Volume$667
Capitalization3.6B
Beam Therapeutics
Price$24.53
Change+$1.09 (+4.65%)
Volume$802.9K
Capitalization2.03B
ACLX vs BEAM Comparison Chart
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACLX vs. BEAM commentary
Jan 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Hold and BEAM is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 22, 2025
Stock price -- (ACLX: $66.57 vs. BEAM: $24.53)
Brand notoriety: ACLX and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 116% vs. BEAM: 69%
Market capitalization -- ACLX: $3.6B vs. BEAM: $2.03B
ACLX [@Biotechnology] is valued at $3.6B. BEAM’s [@Biotechnology] market capitalization is $2.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $341.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than ACLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 3 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • ACLX’s TA Score: 3 bullish, 3 bearish.
  • BEAM’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ACLX.

Price Growth

ACLX (@Biotechnology) experienced а +2.97% price change this week, while BEAM (@Biotechnology) price change was +5.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +1.94%, and the average quarterly price growth was -2.87%.

Reported Earning Dates

ACLX is expected to report earnings on May 08, 2025.

BEAM is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($3.6B) has a higher market cap than BEAM($2.03B). BEAM YTD gains are higher at: -1.089 vs. ACLX (-13.196). ACLX has higher annual earnings (EBITDA): -33.12M vs. BEAM (-160.83M). BEAM has more cash in the bank: 926M vs. ACLX (574M). ACLX has less debt than BEAM: ACLX (65.3M) vs BEAM (162M). BEAM has higher revenues than ACLX: BEAM (350M) vs ACLX (156M).
ACLXBEAMACLX / BEAM
Capitalization3.6B2.03B177%
EBITDA-33.12M-160.83M21%
Gain YTD-13.196-1.0891,212%
P/E RatioN/AN/A-
Revenue156M350M45%
Total Cash574M926M62%
Total Debt65.3M162M40%
TECHNICAL ANALYSIS
Technical Analysis
ACLXBEAM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 15 days ago
88%
Bullish Trend 15 days ago
82%
Momentum
ODDS (%)
Bearish Trend 15 days ago
68%
Bearish Trend 15 days ago
89%
MACD
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 15 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 15 days ago
75%
Bullish Trend 15 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 15 days ago
72%
Bullish Trend 15 days ago
83%
Advances
ODDS (%)
Bullish Trend 20 days ago
89%
Bullish Trend 16 days ago
81%
Declines
ODDS (%)
Bearish Trend 23 days ago
76%
Bearish Trend 21 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend 15 days ago
74%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSWWX25.430.31
+1.23%
Loomis Sayles Global Allocation Y
BACAX13.84N/A
N/A
BlackRock Energy Opportunities Inv A
GHTMX12.50N/A
N/A
Goldman Sachs International T/M Eq Instl
JUEZX24.85N/A
N/A
JPMorgan US Equity R2
HRLCX8.24N/A
N/A
Hartford Real Asset C

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+0.14%
DNLI - ACLX
49%
Loosely correlated
+5.06%
KYMR - ACLX
47%
Loosely correlated
+7.61%
RCKT - ACLX
47%
Loosely correlated
-1.45%
RCUS - ACLX
46%
Loosely correlated
+0.78%
BEAM - ACLX
46%
Loosely correlated
+4.65%
More